QQQ   443.45 (+1.01%)
AAPL   178.00 (-1.52%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.69 (-0.56%)
AMZN   177.89 (+0.64%)
TSLA   200.79 (-0.54%)
NVDA   818.52 (+3.46%)
NIO   5.82 (+1.22%)
AMD   199.64 (+3.69%)
BABA   74.94 (+1.23%)
T   16.93 (+0.00%)
F   12.49 (+0.40%)
MU   95.48 (+5.37%)
CGC   3.26 (-0.91%)
GE   158.79 (+1.21%)
DIS   111.60 (+0.02%)
AMC   4.42 (+2.31%)
PFE   26.54 (-0.08%)
PYPL   60.31 (-0.05%)
XOM   106.22 (+1.63%)
QQQ   443.45 (+1.01%)
AAPL   178.00 (-1.52%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.69 (-0.56%)
AMZN   177.89 (+0.64%)
TSLA   200.79 (-0.54%)
NVDA   818.52 (+3.46%)
NIO   5.82 (+1.22%)
AMD   199.64 (+3.69%)
BABA   74.94 (+1.23%)
T   16.93 (+0.00%)
F   12.49 (+0.40%)
MU   95.48 (+5.37%)
CGC   3.26 (-0.91%)
GE   158.79 (+1.21%)
DIS   111.60 (+0.02%)
AMC   4.42 (+2.31%)
PFE   26.54 (-0.08%)
PYPL   60.31 (-0.05%)
XOM   106.22 (+1.63%)
QQQ   443.45 (+1.01%)
AAPL   178.00 (-1.52%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.69 (-0.56%)
AMZN   177.89 (+0.64%)
TSLA   200.79 (-0.54%)
NVDA   818.52 (+3.46%)
NIO   5.82 (+1.22%)
AMD   199.64 (+3.69%)
BABA   74.94 (+1.23%)
T   16.93 (+0.00%)
F   12.49 (+0.40%)
MU   95.48 (+5.37%)
CGC   3.26 (-0.91%)
GE   158.79 (+1.21%)
DIS   111.60 (+0.02%)
AMC   4.42 (+2.31%)
PFE   26.54 (-0.08%)
PYPL   60.31 (-0.05%)
XOM   106.22 (+1.63%)
QQQ   443.45 (+1.01%)
AAPL   178.00 (-1.52%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.69 (-0.56%)
AMZN   177.89 (+0.64%)
TSLA   200.79 (-0.54%)
NVDA   818.52 (+3.46%)
NIO   5.82 (+1.22%)
AMD   199.64 (+3.69%)
BABA   74.94 (+1.23%)
T   16.93 (+0.00%)
F   12.49 (+0.40%)
MU   95.48 (+5.37%)
CGC   3.26 (-0.91%)
GE   158.79 (+1.21%)
DIS   111.60 (+0.02%)
AMC   4.42 (+2.31%)
PFE   26.54 (-0.08%)
PYPL   60.31 (-0.05%)
XOM   106.22 (+1.63%)
NASDAQ:PCRX

Pacira BioSciences (PCRX) Stock Price, News & Analysis

$29.12
-0.60 (-2.02%)
(As of 11:57 AM ET)
Today's Range
$28.86
$30.01
50-Day Range
$27.70
$35.48
52-Week Range
$25.93
$48.60
Volume
223,141 shs
Average Volume
503,834 shs
Market Capitalization
$1.35 billion
P/E Ratio
323.56
Dividend Yield
N/A
Price Target
$51.44

Pacira BioSciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
73.3% Upside
$51.44 Price Target
Short Interest
Bearish
8.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.89
Upright™ Environmental Score
News Sentiment
0.05mentions of Pacira BioSciences in the last 14 days
Based on 26 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
21.66%
From $2.17 to $2.64 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.28 out of 5 stars

Medical Sector

149th out of 957 stocks

Pharmaceutical Preparations Industry

60th out of 440 stocks

PCRX stock logo

About Pacira BioSciences Stock (NASDAQ:PCRX)

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

PCRX Stock Price History

PCRX Stock News Headlines

Navigating 4 Analyst Ratings For Pacira BioSciences
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Q4 2023 Pacira Biosciences Inc Earnings Call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Preview: Pacira BioSciences's Earnings
Pacira BioSciences Q4 2023 Earnings Preview
PCRX Mar 2024 32.500 put
PCRX Mar 2024 40.000 call
PCRX May 2024 42.500 call
See More Headlines
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PCRX
CUSIP
69512710
Employees
715
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$51.44
High Stock Price Target
$58.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+73.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$15.91 million
Pretax Margin
1.49%

Debt

Sales & Book Value

Annual Sales
$666.82 million
Cash Flow
$3.99 per share
Book Value
$16.89 per share

Miscellaneous

Free Float
43,373,000
Market Cap
$1.38 billion
Optionable
Optionable
Beta
0.79
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report














PCRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Pacira BioSciences stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PCRX shares.
View PCRX analyst ratings
or view top-rated stocks.

What is Pacira BioSciences' stock price target for 2024?

9 equities research analysts have issued 1 year price targets for Pacira BioSciences' shares. Their PCRX share price targets range from $42.00 to $58.00. On average, they predict the company's share price to reach $51.44 in the next year. This suggests a possible upside of 73.3% from the stock's current price.
View analysts price targets for PCRX
or view top-rated stocks among Wall Street analysts.

How have PCRX shares performed in 2024?

Pacira BioSciences' stock was trading at $33.74 at the beginning of the year. Since then, PCRX shares have decreased by 12.0% and is now trading at $29.68.
View the best growth stocks for 2024 here
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) issued its quarterly earnings data on Tuesday, November, 2nd. The company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.65 by $0.07. The company earned $127.70 million during the quarter, compared to the consensus estimate of $129.69 million. Pacira BioSciences had a net margin of 1.05% and a trailing twelve-month return on equity of 12.16%. Pacira BioSciences's quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.43 earnings per share.

What ETFs hold Pacira BioSciences' stock?
What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $680.0 million-$705.0 million, compared to the consensus revenue estimate of $722.5 million.

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.98%), Frontier Capital Management Co. LLC (4.49%), Dimensional Fund Advisors LP (3.04%), Stephens Investment Management Group LLC (2.84%), Vestal Point Capital LP (2.58%) and Clearbridge Investments LLC (2.47%). Insiders that own company stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends
.

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PCRX) was last updated on 3/1/2024 by MarketBeat.com Staff

From Our Partners